COMMUNIQUÉS West-GlobeNewswire

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
02/09/2025
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of [...]
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
02/09/2025
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
02/09/2025
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical [...]
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
02/09/2025
Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline [...]
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
02/09/2025
Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑up SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“ [...]
Neumora Therapeutics to Participate in Upcoming Conferences in September
02/09/2025
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel [...]
AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases
02/09/2025
Two new milestone publications confirm robust efficacy and safety profile of bio-Interventional uveoscleral outflow enhancement technology WHITE PLAINS, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc. today [...]
Kamada to Participate in Upcoming September Investor Conferences
02/09/2025
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious [...]
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
02/09/2025
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
Seer Appoints Isaac Ro to its Board of Directors
02/09/2025
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board [...]
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
02/09/2025
Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further [...]
Trading by management and close relations of management
02/09/2025
Please read the announcement in PDF Attachment 2025_43_Trading_By_Management
Dianabol (Dbol) Pills 2025: DBal Max Launch Dianabol Anabolic Legal Steroid Alternatives for Beginners Dosage Usage, Benefits & Results
02/09/2025
Dianabol (D-bol) Pills for Muscle Growth: Read Benefits, Dianabol Side Effects, Results, and advanced Alternatives Pills From D-Bal Max new york, Sept. 02, 2025 (GLOBE NEWSWIRE) -- August 31, 2025 | New York, (Dbal Max [...]
Military Veterans Join Virtue Recovery to Expand Community Outreach with Hope and Support
02/09/2025
LAS VEGAS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Virtue Recovery is proud to announce the expansion of its Business Development Team with the addition of two U.S. military veterans: Adam Khosroabadi, U.S. Marine Corps [...]
Hemex expands Global Clinical Network Alliance to strengthen end-to-end CRO Capabilities
02/09/2025
A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studies Comprehensive access to international [...]
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
02/09/2025
Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with [...]
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
02/09/2025
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial [...]
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
02/09/2025
The new 5-year strategy, Impact4 , will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to [...]

Pages